Skip to main content
Give
Edit Icon - Click to update your profileUpdate Your Profile

Yixing Jiang, BM, PhD

Academic Title:

Professor

Primary Appointment:

Medicine

Administrative Title:

Chair of Data Safety Monitoring Board, in the Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC)

Additional Title:

Director, GI Medical Oncology Marlene Stewart Greenebaum Cancer Center University of Maryland School of Medicine

Email:

yjiang@umm.edu

Location:

22 S. Greene Street

Phone (Primary):

410-328-4404

Fax:

410-328-2578

Download CV

Education and Training

Bachelor of Medicine (MD Equivalent), Fudan University, College of Medicine, Shanghai

Ph.D., Microbiology, Mount Sinai School of Medicine, New York

Internship, Internal Medicine, Mount Sinai School of Medicine, Bronx Veterans Affair Medical Center

Residency, Internal Medicine, Mount Sinai School of Medicine, Bronx Veterans Affair Medical Center

Fellowship, Hematology/Oncology, the University of Texas MD Anderson Cancer Center

 

Biosketch

As a medical oncologist, my research interest is focused on the following aspects in gastrointestinal malignancies: 1) Drug development and early phase clinical trials: I have worked with NCI and industry in developing and participation of early phase clinical trials. As part of the Mayo consortium, I have experiences working with multiple institutions in early phase clinical trials sponsored by NCI. I have also developed and completed an investigator-initiated phase I study in pancreatic cancer funded by Genentech. Most recently, we have worked with Keystone Nano to develop the first-in-human phase I study of ceramide nanoplipsome in solid tumors. The study is successfully funded by NCI via SBIR mechanism. The study is currently up running and actively enrolling patients.  2) Identification of predictive, prognostic markers and potential new therapeutic targets in gastrointestinal tumors by lipidomics. In collaboration with Dr. Mark Kester at University of Virginia and Dr. Tod Fox at Penn State College of Medicine, we utilized a mass spectrometry-based lipidomic approach to quantify sphingolipids changes in human pancreatic cancer tissues and plasma specimens from patients with pancreatic cancer. The analysis showed that long chain ceramide (C16:0 and C24:0) lipids increased significantly in pancreatic cancer specimen but not in pancreatitis or normal pancreatic tissues. This increase was associated with nodal metastasis and inferior survival. The mechanisms of such alteration are being actively explored. 3) Chemotherapy-related peripheral neuropathy. Chemotherapy-induced peripheral neuropathy has a significant adverse effect on quality of life in long-term cancer survivors. Pharmacological intervention is generally not effective. I have been actively working with Dr. Kathleen Griffith on patient-base studies to develop preventive measurements in patients receiving chemotherapy agents cause neuropathy.

Highlighted Publications

Jiang Y, Wang L, Gong W, Le X, Huang S, Yao J, Ajani J, Abbruzzese JL and Xie K. (2004) A High Level Expression of Insulin-like Growth Factor I receptor is Associated with Increased Expression of Transcription Factor Sp1 and Regional Lymphnode Metastasis of Human Gastric Cancer. Clinical and Experimental Metastasis 21 (2004): 755-764.

Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol. 2012, Jul;24(4):448-53.

Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014 Jul;74(1):205-10.

Additional Publication Citations

  1. Xiong QH, Guo X, Zong C, Jiang Y, Joseph Chan and Lu-Hai Wang. (1996) Cloning and Expression of Chicken Protein Tyrosine Phosphatase gamma.  J. Biomed. Sci. 3: 266-274.
  2. Zong CS, Zeng L, Jiang Y, Sadowski HB and Wang LH. (1998). Stat3 Plays an Important Role in Oncogenic Ros- and Insulin-like Growth Factor I Receptor Induced Anchorage Independent Growth.  J. Biol Chem. 273(43):28065-72.
  3. Jiang Y, Chan J, Zong C and Wang LH. (1996). Effect of Tyrosine Mutations on the Kinase Activity and Transforming Potential of an Oncogenic Human Insulin-like Growth Factor Receptor.  J. Biol. Chem. 271:160-167.
  4. Weiqun Li, Jiang Y, Jiachang Zhang, Lilian Soon, Lawrence Flechner, Veena Kapoor, Jacalyn H. Pierce, and Lu-hai Wang. (1998). Protein Kinase C-delta is an Important Signaling Molecule in Insulin-like Growth Factor I Receptor-mediated Cell Transformation. Mol. Cell Biol. 18(10):5888-98.
  5. Jiang Y, Rom WN, Yie T, Chi C, Tchou-Wong KM. (1999). Induction of Tumor Suppression and Glandular Differentiation of the A549 Lung Carcinoma Cells by Stable Expression of a Dominant-negative Mutant of IGF-I Receptor. Oncogene. 18(44):6071-7.
  6. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM. (2000) Molecular and genetic aspects of lung cancer : Am J Respir Crit Care Med.161(4 Pt 1):1355-67.
  7. Jiang Y, Long Cui, Ting-an Yie, William N. Rom, Hua Cheng and Kam-Men Tchou Wong. (2001). Inhibition of Cellular Tansformation and Distal Metastasis of Human Lung Adenocarcinoma Cells by IkBb. Oncogene 2001(18):2254-63.
  8. Sachdev P, Jiang Y, Li W, Miki T, Maruta H, Nur-E-Kamal MS, Wang LH.(2001) Differential Requirement for Rho Family GTPases in an Oncogenic Insulin-like Growth Factor-I Receptor-induced Cell Transformation. J Biol Chem 276(28):26461-71.
  9. Tchou-Wong KM, Jiang Y, Yee H, LaRosa J, Lee TC, Pellicer A, Jagirdar J, Gordon T, Goldberg JD, Rom WN. (2002) Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer. Am J Respir Cell Mol Biol. 2002, 27(2):186-93.
  10. Jiang Y, Wang L, Gong W, Le X, Huang S, Yao J, Ajani J, Abbruzzese JL and Xie K. (2004) A High Level Expression of Insulin-like Growth Factor I receptor is Associated with Increased Expression of Transcription Factor Sp1 and Regional Lymphnode Metastasis of Human Gastric Cancer. Clinical and Experimental Metastasis 21 (2004): 755-764.
  11. Gong W, Jiang Y, Wang L, Wei D, Yao J, Huang S, Fang S, Xie K. (2005) Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res. 2005, 15;11(16):5778-83.
  12. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. (2006) A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul;24(4):353-7.
  13. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, Wei D, Yao J, Fang S, Xie K.  Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006 23 (7-8):401-10.
  14. Jiang, Y and Cheng, H (2007) The Evidence of LAT as a Dual Substrate for Both Lck and Syk Kinases in T lymphocytes. Leukemia Research 2007, 31 (4): 541-5.
  15.  Kimchi ET, Zeh H, Jiang Y, Staveley-O’Carroll K, Soft Tissue Sarcoma ASC Surgery Principles and Practice book chapter, (2007).
  16. Jiang, Y, Montero AJ, and Staveley-O’Carroll KF (2007) Adjuvant and Preoperative Therapy of Localized Gastric Cancer. Gastrointestinal Cancer Research 2007 Vol 1 (4):139-145.
  17. Yan G, Huang J, Jarbadan NR, Jiang Y, Cheng H. Sequestration of NF-kappaB signaling complexes in lipid rafts contributes to repression of NF-kappaB in T lymphocytes under hyperthermia stress. J Biol Chem. 2008 May 2;283(18):12489-500.
  18. Jiang Y, Lee M, Montero AJ, Kimchi ET, Nikfarjam M and Staveley-O’Carroll KF. Optimizing Imatinib Mesylate in Gastrointestinal Stromal Tumors. Gastrointestinal Cancer Research 2008 Volume 2 issue 5, 245-250.
  19. Jiang Y, Kimchi ET, Montero AJ, Staveley-O’Carroll KF and Ajani JA. Upper Gastrointestinal Tumors: current status and future perspectives. Expert Rev. Anticancer Ther. 2008 Jun;8(6):975-91.
  20. Nikfarjam M, Kimchi E, Shereef S, Gusani NJ, Jiang Y, Liang J, Sehmbey M, Staveley-O'Carroll KF. Surgical Outcomes of Patients with Gastrointestinal Stromal Tumors in the Era of Targeted Drug Therapy. J Gastrointest Surg. 2008 Jun 11.
  21. Nikfarjam M, Shereef S, Kimchi ET, Gusani NJ, Jiang Y, Avella DM, Mahraj RP, Staveley-O'Carroll KF. Survival Outcomes of Patients with Colorectal Liver Metastases Following Hepatic Resection or Ablation in the Era of Effective Chemotherapy. Ann Surg Oncol. 2008 Nov 27.
  22. Jiang Y, Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? Future Oncol. 2009 Mar;5(2):157-61.
  23. Jiang Y, Kimch E, Staveley-O’Carroll KF, Cheng H and Ajani JA.  Assessment k-ras Mutation: A Step toward Personalized Medicine for Patients with Colorectal Cancer Cancer 2009 Aug 15;115(16):3609-17.
  24. Jiang Y. Advanced gastric cancer: a disease of diverse clinical biology. Gastrointest Cancer Res. 2009 May;3(3):125-6.
  25. Gusani NJ, Schubart JR, Wise J, Farace E, Green MJ, Jiang Y, Kimchi ET, Staveley-O'Carroll KF. Cancer survivorship: a new challenge for surgical and medical oncologists J Gen Intern Med. 2009 Nov;24 Suppl 2:S456-8.
  26. Gusani NJ, Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. New pharmacological developments in the treatment of hepatocellular cancer. Drugs. 2009;69(18):2533-40.
  27. Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw. 2010 Jan;8(1):135-44.
  28. Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, Ajani JA. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr;8(4):417-25.
  29. Jiang Y, Owonikoko TK, Ramalingam SS, Khuri FR, Belani CP.  What is the role of maintenance therapy in the treatment of non-small cell lung cancer?  Therapeutic Advances in Medical Oncology, [in print] 2010.
  30. Ayoola, A, Jiang Y, Belani CP.  Cetuximab: The Emerging Evidence of Its Therapeutic Value in Squamous Cell Carcinoma of the Head and Neck.  Clinical Medicine Reviews in Oncology, [in print] 2010.
  31. Jiang Y and Ajani. Multidisciplinary Management of Gastric Cancer. Curr Opin Gastroenterol. 2010 Nov;26(6):640-6.
  32. Deshaies I, Cherenfant J, Gusani NJ, Jiang Y, Harvey HA, Kimchi ET, Kaifi JT, Staveley-O'Carroll KF. Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. Ther Clin Risk Manag. 2010 Oct 5;6:453-8
  33. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, Kimchi ET, Jiang Y, Isom HC, Kester M, Staveley-O'Carroll KF. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut. 2011 May;60(5):695-701.
  34. Kaifi JT, Gusani NJ, Jiang Y, Mackley HB, Dye CE, Mathew A, Kimchi ET, Reed MF, Staveley-O'carroll KF. Multidisciplinary management of early and locally advanced esophageal cancer. J Clin Gastroenterol. 2011 May-Jun;45(5):391-9.
  35. You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in Hepatocellular carcinoma. Hepatology. 2011 May 26. doi: 10.1002/hep.24450.
  36. Rizvi S, Fateh S, Abbi KK, Jiang Y. Leptomeningeal carcinomatosis as the only manifestation of disease in recurrent gastroesophageal cancers. Gastrointest Cancer Res. 2011 Mar;4(2):68-71.
  37. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, Kimchi ET, Jiang Y, Isom HC, Kester M, Staveley-O'Carroll KF. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut. 2011 May;60(5):695-701.
  38. Jiang Y, Divittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biol Ther. 2011 Oct 1;12(7).
  39. Joshi M, Jiang Y, Belani CP. Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. Expert Opin Pharmacother. 2012 Apr;13(5):685-97. Epub 2012 Mar 10.
  40. Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol. 2012 Jul;24(4):448-53.
  41. Jiang Y, DiVittore NA, Young MM, Jia Z., Xie P, Ritty TM, Kester M and Fox TE. Altered Sphingolipid Metabolism in Patients with Metastatic Pancreatic Cancer. Biomolecules 2013, 3(3), 435-448; doi:10.3390/biom3030435
  42. Jiang Y. Impact of genetic targets on cancer therapy in esophagogastric cancer. Adv Exp Med Biol.2013;779:55-65. doi: 10.1007/978-1-4614-6176-0_3.
  43. Reddy SK, Reilly C, Zhan M, Mindikoglu AL, Jiang Y, Lane BF, Alexander HR, Culpepper WJ, El-Kamary SS. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol. 2014 Jun;31(6):971. doi: 10.1007/s12032-014-0971-y. Epub 2014 May 6.
  44. Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014 Jul;74(1):205-10
  45. Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.  A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent. Clin Cancer Res. 2015 Feb 15;21(4):721-9.

Research Interests

Drug Development and Early Phase Clinical Trials

Drug development and early phase clinical trials are extremely important in today’s oncological therapy. My research has been focused on the following aspects of drug development: 1) pre-clinical studies This part of research involves screening new therapeutics in tissue cultures and mice in vivo models. For example, we successful assessed the anti-tumor efficacy of Ceramide nanoliposome in these pre-clinical studies. 2) Phase I clinical studies This part research mainly focuses on assess the toxicity profiles of new therapeutics either as single agent or in combination with other drugs. For an instance, we have established the safety of chemotherapy agent capecitabine and a biological agent, erlotinb, concurrent with radiation in patients with inoperable adenocarcinoma of the pancreas.

  1. Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE. A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent. 2015 Feb 15;21(4):721-9. PMID: 25467180.
  2. Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014 Jul;74(1):205-10.
  3. Jiang Y, Divittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M. Combinatorial Therapies Improve the Therapeutic Efficacy of Nanoliposomal Ceramide for Pancreatic Cancer. Cancer Biol Ther 2011 Oct 1;12(7). PMID: 21795855.
  4. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. (2006) A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul;24(4):353-7. PMID: 16683077.

Identification of Potential Biomarkers and Therapeutic Targets in Gastrointestinal Tumors

  1. Jiang Y, DiVittore NA, Young MM, Jia Z., Xie P, Ritty TM, Kester M and Fox TE. Altered Sphingolipid     Metabolism in Patients with Metastatic Pancreatic Cancer. Biomolecules 2013, 3(3), 435-448.
  2. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, Wei D, Yao J, Fang S, Xie K.  Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006 23 (7-8):401-10. PMID: 17187227.
  3. Gong W, Jiang Y, Wang L, Wei D, Yao J, Huang S, Fang S, Xie K. (2005) Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res. 2005, 15;11(16):5778-83. PMID:16115916.
  4. Jiang Y, Wang L, Gong W, Le X, Huang S, Yao J, Ajani J, Abbruzzese JL and Xie K. (2004) A High Level Expression of Insulin-like Growth Factor I receptor is Associated with Increased Expression of Transcription Factor Sp1 and Regional Lymphnode Metastasis of Human Gastric Cancer. Clinical and Experimental Metastasis 21 (2004): 755-764. PMID: 16035620.

 

Links of Interest

http://www.umm.edu/programs/cancer/

Edit Icon - Click to update your profileUpdate Your Profile